A compound, or a pharmaceutically acceptable salt or isomer thereof, of Formula I: ##STR00001## wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl; R.sup.1 is hydrogen, alkoxy, or substituted alkoxy; R.sup.2 is hydrogen, alkyl, or substituted alkyl; and R.sup.3 is hydrogen, alkyl, or substituted alkyl.

The present disclosure describes novel TRK kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such TRK kinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also described.

The present invention discloses Octenidine based compounds of formula (A) or formula (B) and formula (C) where in, n=1, 2, 3, 4 and R′=un-substituted or substituted aryl or alkyl group; R is hydroxy or hydrogen, X is chlorine, bromine and iodine. The present invention also relates to a process for the preparation thereof.

The present invention provides novel compounds with improved solubility and altered pharmacokinetic properties. The compounds of the present invention may be represented by Formula I as below:

##STR00001##

The present invention provides novel compounds with improved solubility and altered pharmacokinetic properties. The compounds of the present invention may be represented by Formula I as below:

##STR00001##

Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.

The present invention discloses Octenidine based compounds of formula (A) or formula (B) and formula (C) where in, n=1,2,3,4 and R=un-substituted or substituted aryl or alkyl group; R is hydroxy or hydrogen, X is chlorine, bromine and iodine. The present invention also relates to a process for the preparation thereof.

The present disclosure relates to the preparation of pyridine derivatives, such as -picoline or -parvoline, and catalysts useful for the selective preparation of such pyridine derivatives. Particularly, the present disclosure relates to the selective preparation of certain pyridine derivative using dealuminated zeolite catalysts.

The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

##STR00001##

The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

##STR00001##